Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,910 matching trials from the live ClinicalTrials.gov search.
Conditions
Male Erectile Disorder, Prostate Cancer, Sexual Dysfunction
Interventions
Sexual Health Inventory for Men (SHIM) questionnaire administration, management of therapy complications, Daily vacuum therapy
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Up to 70 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
68Ga-PSMA-11, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
Interventions
FK-PC101, Standard of Care (SOC)
Biological
Lead sponsor
Cellvax Therapeutics Inc
Industry
Eligibility
Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Gahanna, Ohio • Myrtle Beach, South Carolina
Conditions
Prostatic Neoplasms
Interventions
CC-94676, CC1083611, CC1083610
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
19
States / cities
Stanford, California • Washington D.C., District of Columbia • Sarasota, Florida + 14 more
Conditions
Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Nicotine Replacement Patch
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
MLN0128
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rucaparib, Enzalutamide, Abiraterone
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Nashville, Tennessee
Conditions
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
Interventions
225Ac-ETN029, 111In-ETN029
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more
Conditions
Prostate Carcinoma
Interventions
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
21 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
345
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 224 more
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
374
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
Conditions
Bladder Cancer
Interventions
biopsy, therapeutic conventional surgery
Procedure
Lead sponsor
Roei Medical Technologies Ltd.
Industry
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostatic Neoplasms, Bone Mineral Density Quantitative Trait Locus 3
Interventions
vitamin D, Placebo
Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
60 Years to 99 Years · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, New York
Conditions
Prostate Cancer Metastatic
Interventions
REGN2810, Degarelix, Leuprolide Acetate, Docetaxel
Drug
Lead sponsor
Mark Stein
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Interventions
GVV858, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas
Conditions
Prostatic Neoplasm
Interventions
Xofigo (Radium 223 dichloride,BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older · Male only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Whippany, New Jersey
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
Drug · Diagnostic Test · Procedure
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Conditions
Prostate Cancer
Interventions
GTx-758
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
San Bernardino, California • Jeffersonville, Indiana • Albuquerque, New Mexico + 4 more
Active, not recruiting Phase 3 Interventional Results available

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197
Conditions
mCRPC
Interventions
Talazoparib with enzalutamide, Placebo with enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
132
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 93 more
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Stage IV Prostate Cancer
Interventions
bicalutamide, raloxifene, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Recurrent Prostate Cancer
Interventions
computed tomography, bone scan, 3-Tesla magnetic resonance imaging, diffusion-weighted magnetic resonance imaging, fluorine F 18 sodium fluoride, positron emission tomography, laboratory biomarker analysis
Procedure · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Conditions
Recurrent Prostate Cancer
Interventions
MGE, Placebo, ADT
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Conditions
Metastatic Prostate Cancer
Interventions
High dose testosterone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more
Conditions
Infection
Interventions
Transperineal MRI-guided prostate biopsy, Transrectal MRI-guided prostate biopsy, Antibiotic (prophylaxis)
Procedure · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
SX-682, Enzalutamide
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Ann Arbor, Michigan + 3 more